Search - tctmd.com

Displaying 281 - 300 of 367

Sort: Relevancy | Date

News Conference News EAS 2018

Can Clinicians Really Put a Stop to Atherosclerosis? Experts Explore the How and When of CVD Prevention

Yael L. Maxwell

May 07, 2018

News Daily News

Alirocumab Price Slashed in Deal With Express Scripts

Michael O'Riordan

May 03, 2018

News Daily News

LPA Variants Linked With CHD Events in Statin-Treated Patients

Michael O'Riordan

May 03, 2018

News Daily News

The Higher the LDL, the Bigger the Mortality Benefit of Intensive Therapy: Meta-analysis

Michael O'Riordan

April 20, 2018

News Daily News

Nearly Half of Acute MI Patients Under Age 50 May Have Metabolic Syndrome

L.A. McKeown

April 19, 2018

News Daily News

More Awareness of Familial Hypercholesterolemia and Severe Dyslipidemia, yet Statin Use Remains Low

Yael L. Maxwell

March 28, 2018

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

News Conference News ACC 2018

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

Michael O'Riordan

March 14, 2018

News Conference News ACC 2018

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Michael O'Riordan

March 10, 2018

News Daily News

Bempedoic Acid Phase III Trial Meets Primary Endpoint for Cutting LDL Cholesterol

Yael L. Maxwell

March 08, 2018

News Daily News

Maze of Prior Authorization for PCSK9 Inhibitors Poses Challenge to Prescribers

Yael L. Maxwell

January 24, 2018

News Daily News

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

Michael O'Riordan

January 19, 2018

News Daily News

Bariatric Surgery: Cardiometabolic Benefits Down, but Not Out, at 5 Years

Michael O'Riordan

January 18, 2018

News Daily News

Role of Lp(a) Still to Be Determined, but NHLBI Sees a Path Forward

Michael O'Riordan

January 09, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

Subclinical Atherosclerosis Evident in Half of Adults Without CVD Risk Factors

Michael O'Riordan

December 12, 2017

News Daily News

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Michael O'Riordan

December 04, 2017

News Conference News AHA 2017

Missed by Risk Calculators, Few Young MI Patients Were Previously on Statins

Caitlin E. Cox

November 14, 2017

News Conference News AHA 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Yael L. Maxwell

November 13, 2017

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

Advertisement

Can Clinicians Really Put a Stop to Atherosclerosis? Experts Explore the How and When of CVD Prevention

Alirocumab Price Slashed in Deal With Express Scripts

LPA Variants Linked With CHD Events in Statin-Treated Patients

The Higher the LDL, the Bigger the Mortality Benefit of Intensive Therapy: Meta-analysis

Nearly Half of Acute MI Patients Under Age 50 May Have Metabolic Syndrome

More Awareness of Familial Hypercholesterolemia and Severe Dyslipidemia, yet Statin Use Remains Low

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Bempedoic Acid Phase III Trial Meets Primary Endpoint for Cutting LDL Cholesterol

Maze of Prior Authorization for PCSK9 Inhibitors Poses Challenge to Prescribers

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

Bariatric Surgery: Cardiometabolic Benefits Down, but Not Out, at 5 Years

Role of Lp(a) Still to Be Determined, but NHLBI Sees a Path Forward

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Subclinical Atherosclerosis Evident in Half of Adults Without CVD Risk Factors

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Missed by Risk Calculators, Few Young MI Patients Were Previously on Statins

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content